News
Updates
Regulatory movement, what the research actually establishes, and changes to how this site works. Positions in this category move, every compound page carries the date we last checked, and when one changes it gets written up here rather than quietly edited.
Subscribe by RSS — no account, no email address, and we cannot see who is reading.
Regulatory
A GLP-1 ingredient maker was stopped at the border. The vendors we index were never eligible to be.
Chengdu Shengnuo Biopharm went onto FDA Import Alert 66-40 on 19 September 2026 and suspended all peptide ingredient sales to the US. The listing covers all its drugs, not only peptides — and an import alert is a tool that only works on a supplier the FDA can find.
Federal agents searched a peptide seller's address. Nobody has said it was about peptides.
Federal agents searched a North Sioux City building tied to Apex Peptides on 23 September 2026. No charges, no affidavit, and no agency has said what the investigation is about. The FDA is not one of the agencies involved, which is most of what the coverage gets wrong.
The FDA objected twice before this GLP-1 supplement shipped. It is still on sale.
Warning letter 731846 objects to both new dietary ingredient notifications BioDrive filed for the peptide in Evolv GLP-1 Biomimetic. Published on 22 September 2026, it cites potential toxicity. The tablet went on sale anyway, and is on sale today.
Semaglutide is still not prohibited in sport. Most of what this site covers is.
WADA's 2027 Prohibited List keeps GLP-1 receptor agonists off it and on the Monitoring Program instead. The compounds sold beside them on the same vendor pages are prohibited at all times — not because anyone voted on them, but because nobody approved them.
The FDA says the prescriptions that made this compounding legal were copy-pasted
A warning letter to one of the largest compounding pharmacies in the United States alleges copied clinical judgements. The reasoning that justifies compounding a copy of an approved drug appeared word for word across many patient records, which goes to what the word compounded means.
An FDA panel voted to let pharmacies compound BPC-157 and TB-500. That is not the same as legal.
Six peptides were recommended for the 503A bulks list on 23 and 24 July 2026, every one of them by a narrow margin. What a recommendation opens is a prescription filled by a pharmacy, and it does not reach a vial bought under a research label.
A peptide seller was sentenced to 70 months. He admitted forging the certificates.
Paradigm Peptides' owner was sentenced on 30 July 2026. Six products sold as SARMs all contained testosterone, and the laboratory certificates behind them were forged. It is the clearest evidence yet of what a certificate of analysis is worth.
Orforglipron is approved, and it is not a peptide. Both halves matter.
Approved on 1 April 2026 as Foundayo: the first GLP-1 that is a true small molecule, taken as a tablet with no food or timing rules. Across the 94 vendors we read, exactly one sells it — and the chemistry explains why.
GLP-1, GLP-2 and GLP-3 on a vendor listing are not what they sound like
Twenty of the vendors we read have stopped printing 'semaglutide' and 'tirzepatide' at all. The code they use instead is consistent across the market, and it is not pharmacology.
What a certificate of analysis actually proves
A COA is a lab report on a sample, commissioned by the seller. That is worth something, and it is worth considerably less than it is usually taken to mean.
What 'research chemical' actually means on a peptide vial
The label is a legal position, not a quality grade. It says nothing about what is in the vial, and that is the point of it.
GLP-1 compounds: the gap between the trials and the vial
Semaglutide and tirzepatide have large phase 3 programmes behind them. What those programmes tested was a manufactured medicine, not a vial bought under a research label.
Research
ACE-031 was stopped in a trial in children. It is still on sale.
A myostatin trap that reached phase 2 in Duchenne muscular dystrophy, halted after the second dosing regimen for nosebleeds and burst capillaries. Seven of the vendors we track list it.
NNMT inhibitors and the NAD+ story: a chain of plausible links
5-Amino-1MQ is sold on a mechanism with support at every step and no human trial at any step. That combination is worth understanding on its own terms.
Retatrutide: what the phase 3 programme does and does not settle
The largest reported weight reduction in the incretin class, from trials that are still running. What that means for a compound already being sold everywhere.
Site update
The cheapest listing in our index was not a listing at all
Two cents a milligram sat at the bottom of the price index for weeks. The number came from the compound's own name, and finding it is the argument for showing our working.
We were filing nootropics under anti-aging. They have their own page now.
Thirteen compounds sat in the longevity category because there was nowhere else to put them. A third of that page was not about ageing, which made both groups less useful.
Why we price per milligram, and what that hides
A 10 mg vial at $35 and a 5 mg vial at $20 are not comparable until you divide. Normalising is the only way to compare, and it quietly assumes things worth naming.
How we track regulatory status, and why every line has a date
Every compound page carries a regulatory line with the date we last checked it. Here is what that date means and what it does not.
Next